Originally published: Regenerex Article
Download PDF
Author:
Regenerex
Summary:
Accelerex is a sterile wound ointment with the patented active ingredient QBX, which is designed to regulate the production of matrix metalloproteases (MMPs) at the cellular level in acute and chronic wounds. It has also been marketed under the names DerMax, Epi-Max, and 3M Tagaderm Matrix.
When applied, body heat melts the ointment, keeping the wound moist and releasing QBX. QBX then alters the micro-environment by reducing MMP production, allowing the body’s natural healing process to resume. Clinical trials have shown Accelerex to be effective in healing chronic wounds, particularly diabetic foot ulcers, with a 96% wound closure rate in less than 12 weeks when used with the entire Regenerex system.
Chronic wounds are characterized by delayed healing and resistance to conventional treatments, often due to elevated MMP levels and persistent overproduction of reactive oxygen species (ROS). Accelerex’s QBX technology works by delivering metal ions to regulate gene expression for MMPs and their natural inhibitors (TIMPs), bringing them into balance. It also normalizes wound pH and reduces ROS activity.
Regenerex, founded by Mr. Pilant, has expanded the wound healing system by adding synergistic products that eradicate bacteria and fight Biofilms, further increasing the success rate and speed of closing chronic wounds. These products incorporate QBX technology with peptide and anti-biofilm technologies. Mr. Pilant has also developed proprietary formulations to destroy pathogens like C. difficile, E. coli, and MRSA, which are effective in killing biofilms in wound beds.
In normal wound progression, proteases clean the wound, growth factors heal it, and control bacteria down-regulate proteases. In chronic wounds, proteases increase, growth factors are neutralized, and bad bacteria and biofilms increase. Regenerex corrects chronicity by lowering MMP production, stimulating growth factor production, and regulating harmful bacteria and biofilms.
